Beneficial effects of thiazolidinediones on diabetic nephropathy in OLETF rats

Mi Young Lee, Eun Young Lee, Byung Jun Lee, Chan Sik Won, Jang Hyun Koh, Jang Yel Shin, Young Goo Shin, Byung Pil Cho, Choon Hee Chung

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Purpose: Diabetic nephropathy is the most serious of complications in diabetes mellitus. Thiazolidinedione (TZD) is thought to ameliorate diabetic nephropathy; however, the mechanism underlying this effect has not been elucidated. We hypothesized that the vascular endothelial growth factor (VEGF) participates in the pathogenesis of diabetic nephropathy and that TZD may be beneficial for the treatment of diabetic nephropathy because of the effect it has on VEGF. Materials and Methods: 23 Otsuka- Long-Evans-Tokushima-Fatty (OLETF) rats and eight control Long-Evans-Tokushima-Otsuka (LETO) rats were divided into the following four groups: LETO group, control OLETF group, pioglitazone treated group (10 mg/kg/day), and rosiglitazone treated group (3 mg/kg/day). Results: A progressive increase in urinary protein excretion was observed in the diabetic rats. Glomerular VEGF expression in the control OLETF rats was significantly higher than in the control LETO rats. However, there was a significant reduction in both the glomerular VEGF expression and the VEGF mRNA levels after treatment with pioglitazone and rosiglitazone. The twenty-four hour urine protein levels were significantly decreased in both groups of the treated OLETF rats. Conclusion: These results suggest that TZD may have beneficial effects on diabetic nephropathy by reducing the VEGF expression.

Original languageEnglish
Pages (from-to)301-307
Number of pages7
JournalYonsei medical journal
Volume48
Issue number2
DOIs
Publication statusPublished - 2007 Apr 1

Fingerprint

Inbred OLETF Rats
Thiazolidinediones
Diabetic Nephropathies
Vascular Endothelial Growth Factor A
rosiglitazone
pioglitazone
Diabetes Complications
Proteins
Urine
Control Groups
Messenger RNA

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Lee, Mi Young ; Lee, Eun Young ; Lee, Byung Jun ; Won, Chan Sik ; Koh, Jang Hyun ; Shin, Jang Yel ; Shin, Young Goo ; Cho, Byung Pil ; Chung, Choon Hee. / Beneficial effects of thiazolidinediones on diabetic nephropathy in OLETF rats. In: Yonsei medical journal. 2007 ; Vol. 48, No. 2. pp. 301-307.
@article{710b49750131431591591ee6cf5a6109,
title = "Beneficial effects of thiazolidinediones on diabetic nephropathy in OLETF rats",
abstract = "Purpose: Diabetic nephropathy is the most serious of complications in diabetes mellitus. Thiazolidinedione (TZD) is thought to ameliorate diabetic nephropathy; however, the mechanism underlying this effect has not been elucidated. We hypothesized that the vascular endothelial growth factor (VEGF) participates in the pathogenesis of diabetic nephropathy and that TZD may be beneficial for the treatment of diabetic nephropathy because of the effect it has on VEGF. Materials and Methods: 23 Otsuka- Long-Evans-Tokushima-Fatty (OLETF) rats and eight control Long-Evans-Tokushima-Otsuka (LETO) rats were divided into the following four groups: LETO group, control OLETF group, pioglitazone treated group (10 mg/kg/day), and rosiglitazone treated group (3 mg/kg/day). Results: A progressive increase in urinary protein excretion was observed in the diabetic rats. Glomerular VEGF expression in the control OLETF rats was significantly higher than in the control LETO rats. However, there was a significant reduction in both the glomerular VEGF expression and the VEGF mRNA levels after treatment with pioglitazone and rosiglitazone. The twenty-four hour urine protein levels were significantly decreased in both groups of the treated OLETF rats. Conclusion: These results suggest that TZD may have beneficial effects on diabetic nephropathy by reducing the VEGF expression.",
author = "Lee, {Mi Young} and Lee, {Eun Young} and Lee, {Byung Jun} and Won, {Chan Sik} and Koh, {Jang Hyun} and Shin, {Jang Yel} and Shin, {Young Goo} and Cho, {Byung Pil} and Chung, {Choon Hee}",
year = "2007",
month = "4",
day = "1",
doi = "10.3349/ymj.2007.48.2.301",
language = "English",
volume = "48",
pages = "301--307",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "2",

}

Lee, MY, Lee, EY, Lee, BJ, Won, CS, Koh, JH, Shin, JY, Shin, YG, Cho, BP & Chung, CH 2007, 'Beneficial effects of thiazolidinediones on diabetic nephropathy in OLETF rats', Yonsei medical journal, vol. 48, no. 2, pp. 301-307. https://doi.org/10.3349/ymj.2007.48.2.301

Beneficial effects of thiazolidinediones on diabetic nephropathy in OLETF rats. / Lee, Mi Young; Lee, Eun Young; Lee, Byung Jun; Won, Chan Sik; Koh, Jang Hyun; Shin, Jang Yel; Shin, Young Goo; Cho, Byung Pil; Chung, Choon Hee.

In: Yonsei medical journal, Vol. 48, No. 2, 01.04.2007, p. 301-307.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Beneficial effects of thiazolidinediones on diabetic nephropathy in OLETF rats

AU - Lee, Mi Young

AU - Lee, Eun Young

AU - Lee, Byung Jun

AU - Won, Chan Sik

AU - Koh, Jang Hyun

AU - Shin, Jang Yel

AU - Shin, Young Goo

AU - Cho, Byung Pil

AU - Chung, Choon Hee

PY - 2007/4/1

Y1 - 2007/4/1

N2 - Purpose: Diabetic nephropathy is the most serious of complications in diabetes mellitus. Thiazolidinedione (TZD) is thought to ameliorate diabetic nephropathy; however, the mechanism underlying this effect has not been elucidated. We hypothesized that the vascular endothelial growth factor (VEGF) participates in the pathogenesis of diabetic nephropathy and that TZD may be beneficial for the treatment of diabetic nephropathy because of the effect it has on VEGF. Materials and Methods: 23 Otsuka- Long-Evans-Tokushima-Fatty (OLETF) rats and eight control Long-Evans-Tokushima-Otsuka (LETO) rats were divided into the following four groups: LETO group, control OLETF group, pioglitazone treated group (10 mg/kg/day), and rosiglitazone treated group (3 mg/kg/day). Results: A progressive increase in urinary protein excretion was observed in the diabetic rats. Glomerular VEGF expression in the control OLETF rats was significantly higher than in the control LETO rats. However, there was a significant reduction in both the glomerular VEGF expression and the VEGF mRNA levels after treatment with pioglitazone and rosiglitazone. The twenty-four hour urine protein levels were significantly decreased in both groups of the treated OLETF rats. Conclusion: These results suggest that TZD may have beneficial effects on diabetic nephropathy by reducing the VEGF expression.

AB - Purpose: Diabetic nephropathy is the most serious of complications in diabetes mellitus. Thiazolidinedione (TZD) is thought to ameliorate diabetic nephropathy; however, the mechanism underlying this effect has not been elucidated. We hypothesized that the vascular endothelial growth factor (VEGF) participates in the pathogenesis of diabetic nephropathy and that TZD may be beneficial for the treatment of diabetic nephropathy because of the effect it has on VEGF. Materials and Methods: 23 Otsuka- Long-Evans-Tokushima-Fatty (OLETF) rats and eight control Long-Evans-Tokushima-Otsuka (LETO) rats were divided into the following four groups: LETO group, control OLETF group, pioglitazone treated group (10 mg/kg/day), and rosiglitazone treated group (3 mg/kg/day). Results: A progressive increase in urinary protein excretion was observed in the diabetic rats. Glomerular VEGF expression in the control OLETF rats was significantly higher than in the control LETO rats. However, there was a significant reduction in both the glomerular VEGF expression and the VEGF mRNA levels after treatment with pioglitazone and rosiglitazone. The twenty-four hour urine protein levels were significantly decreased in both groups of the treated OLETF rats. Conclusion: These results suggest that TZD may have beneficial effects on diabetic nephropathy by reducing the VEGF expression.

UR - http://www.scopus.com/inward/record.url?scp=34248151914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248151914&partnerID=8YFLogxK

U2 - 10.3349/ymj.2007.48.2.301

DO - 10.3349/ymj.2007.48.2.301

M3 - Article

VL - 48

SP - 301

EP - 307

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - 2

ER -